Table 1 Inclusion and exclusion criteria for entering the PAHFRAC-01 clinical trial

Age ≥65 years

Bone marrow diseases which could interfere in the erythropoietic process (acute or chronic myelodysplastic syndromes or myeloproliferative diseases, and/or infiltration of the bone marrow due to solid or lymphatic neoplasm)

Osteoporotic hip fracture requiring surgical repair

Blood coagulation diseases or being currently treated with oral anticoagulants and/or heparin at therapeutic doses.

Hemoglobin levels between 90-120 g/L

Documented allergy and/or previous intolerance and/or contraindication of erythropoietin use and/or intravenous iron

Signed informed consent form

Patients with rheumatoid arthritis and/or another demonstrated origin of inflammatory anemia and/or not controlled arterial hypertension

Patients with current or previous treatment for at least 3 months, with erythropoietin or intravenous iron

Patients with chronic renal failure receiving hemodialysis or peritoneal dialysis